ginkgo (Ginkgo biloba)

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies with variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD, peds patients

[Insufficient Evidence]

Dose: 50 mg PO bid; Info: for patients 3-17 yo; used with American ginseng extract

age-related macular degeneration

[Insufficient Evidence]

Dose: 60-240 mg/day PO divided bid-tid

allergic rhinitis

[Insufficient Evidence]

Dose: 2 drops 0.05% in eye(s) tid

altitude sickness prevention

[Insufficient Evidence]

Dose: 80-120 mg PO bid

angina

[Insufficient Evidence]

Dose: 315 mg PO tid; Info: used with standard tx

anxiety

[Possibly Effective]

Dose: 80-160 mg PO tid

chronic fatigue syndrome

[Insufficient Evidence]

Dose: 120-180 mg PO qd

cognitive function

[Insufficient Evidence]

Dose: 240-600 mg PO x1; Alt: 80-300 mg/day PO divided qd-tid

cognitive impairment

[Insufficient Evidence]

Dose: 40 mg PO tid; Alt: 200 mg PO qd starting 48h before electroconvulsive tx, then continue until electroconvulsive tx end

colorectal CA

[Insufficient Evidence]

Dose: 350 mg IV qd on days 1-6 of 21-day cycle; Info: used with 5-FU

dementia

[Possibly Effective]

Dose: 120-240 mg/day PO divided qd-tid; Alt: 150 mg PO tid

diabetes mellitus, type 2

[Insufficient Evidence]

Dose: 120 mg PO qd

diabetic retinopathy

[Insufficient Evidence]

Dose: 120 mg PO qd

dry eye disease

[Insufficient Evidence]

Dose: 1 drop 0.05% in eye(s) tid

dyslexia, peds patients

[Insufficient Evidence]

Dose: 80 mg PO qd; Info: for patients 5-16 yo

fibromyalgia

[Insufficient Evidence]

Dose: 200 mg PO qd; Info: used with coenzyme Q10

gastric CA

[Insufficient Evidence]

Dose: 250 mg PO bid

glaucoma

[Insufficient Evidence]

Dose: 120-160 mg/day PO divided bid-tid

hearing loss

[Possibly Effective]

Dose: 40-175 mg IV qd; Alt: 120 mg PO bid

migraine prophylaxis, adult patients

[Insufficient Evidence]

Dose: 60 mg PO bid

migraine prophylaxis, peds patients

[Insufficient Evidence]

Dose: 80 mg PO bid

pancreatic CA

[Insufficient Evidence]

Dose: 350 mg IV qd on days 1-6 of 21-day cycle; Info: used with 5-FU

Parkinson disease

[Insufficient Evidence]

Dose: 80 mg PO tid

peripheral arterial disease

[Insufficient Evidence]

Dose: 120-240 mg/day PO divided qd-bid

premenstrual syndrome

[Possibly Effective]

Dose: 40 mg PO tid; Alt: 80 mg PO bid; Info: start on day 16, continue until day 5 of next cycle

quality of life

[Insufficient Evidence]

Dose: 120 mg PO qd

radiation dermatitis

[Insufficient Evidence]

Dose: apply cream topically bid-tid; Start: 15 days before XRT

radiation exposure

[Insufficient Evidence]

Dose: 120 mg PO qd

Raynaud phenomenon

[Insufficient Evidence]

Dose: 120 mg PO tid

schizophrenia

[Possibly Effective]

Dose: 120-360 mg PO qd; Info: used with antipsychotic tx

sexual dysfunction

[Insufficient Evidence]

Dose: 150 mg PO bid

stroke

[Possibly Effective]

Dose: 17.5 g IV qd; Alt: 25 mg IV qd x14 days starting within 48h of symptom onset; Info: used with or without standard tx

tardive dyskinesia

[Possibly Effective]

Dose: 80 mg PO tid

vascular dementia

[Possibly Effective]

Dose: 240 mg PO qd

vertigo

[Possibly Effective]

Dose: 120-160 mg/day PO divided qd-bid; Alt: 40 mg PO tid

vitiligo

[Insufficient Evidence]

Dose: 60 mg PO bid